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For the first time in Italy, two patients with meningoencephalitis 
were diagnosed with West Nile virus (WNV) infection in September 
2008 [1]. The patients live in the Bologna and Ferrara provinces of 
Emilia Romagna where WNV infections had previously been noted 
in horses, crows and magpies [2]. 
The Italian National Transplant Centre (CNT), which is responsible 
for the procurement, processing and distribution of organs and 
tissues in Italy, has now reviewed the risks of transmission of WNV 
by organ, tissue and cell transplantation and, taking into account 
the advice and recommendations of the relevant authorities in other 
countries, issued guidance to the transplant community. 
Background
Although there are no known cases of WNV transmission 
by tissue transplantation, both blood transfusion and organ 
transplantation have resulted in transmissions [3-6]. Transmission 
by transplantation of tissues such as bone, heart valves, skin and 
corneas is theoretically possible, particularly when the tissues have 
been minimally processed and/or they contain blood. 
European Union Directive 2006/17/EC, Annex 1, defines the 
criteria to be applied for the selection of tissue and cell donors and 
Annex 2 defines the testing requirements [7]. Annex 1 states that 
donors must be excluded from donation if there is evidence of “risk 
factors for transmissible diseases on the basis of a risk assessment, 
taking into consideration donor travel and exposure history and local 
infectious disease prevalence”. This requirement is reflected in the 
CNT’s Guidelines for the Procurement, Processing and Distribution 
of Tissues for Transplantation (19/06/2007), which demand the 
exclusion of donors who have “a risk of infection associated with 
travel to endemic areas or exposure to infective agents that cannot 
be excluded by testing”.
The Food and Drug Administration (FDA) in the United States 
issued draft, non-binding guidance for blood, cell and tissue 
donations in April 2008 [8]. They recommend that blood specimens 
from all human cell and tissue donors be tested year-round for WNV 
by individual donor Nucleic Acid Testing (NAT) using a licensed 
screening NAT test, and that only donors whose specimens are 
non-reactive may be considered eligible. 
The American Association of Tissue Banks has raised concerns 
about the necessity for universal testing seeing as there are as yet 
no reports of transmission by tissue transplantation. They have 
also raised concerns regarding the reliability of the kits that have 
been licensed for use with post-mortem samples: They report an 
unacceptable rate of abnormal initial tests that give a weak positive 
result but are negative when repeated for the same sample [9]. 
Apart from these concerns, it is relevant that in the case of 
the first donor that transmitted WNV by organ transplantation, 
two serum samples collected at the time of admission did not 
contain any detectable WNV IgM antibody or nucleic acid. Neither 
did a serum sample obtained from the patient on the following 
day, after receipt of transfusions contain detectable levels of WNV 
nucleic acid. However, serum and plasma samples collected a day 
later at the time of organ recovery yielded WNV nucleic acid in 
a quantitative PCR, and WNV could be recovered in culture [4]. 
In the second case of transmission by organ transplantation, the 
donor tested negative for WNV RNA, although serum samples were 
positive for WNV IgG and IgM [5]. 
These findings underline the problems that can arise when 
relying on testing and the importance of accurate documentation of 
the donor’s history in the prevention of donor-transmitted infections 
such as West Nile fever.
It is notable that in the United Kingdom, 18,700 blood donors 
returning from high-incidence WNV areas during the epidemic 
season were tested between mid-June 2004 and the end of 
November 2005 and no positive result was obtained [10]. It can 
be concluded that the risk of transmission by those who have 
travelled to affected areas is very low.
Guidance issued for transplantation in Italy
In the light of the recently reported infections, and taking a 
precautionary approach, the Italian National Transplant Centre 
has issued guidance that all potential donors of organs, tissues 
and cells from the Bologna and Ferrara provinces in the Emilia-
Romagna region should be tested to exclude infection. Where 
there is evidence of infection, organs, tissues and cells will not 
be used.
In the rest of Italy and in the other Emilia-Romagna provinces, 
he following rules apply:
• Investigation of the history of potential tissue donors will include 
enquiries regarding a possible overnight stay in the provinces 
of Bologna and/or Ferrara during the previous 28 days. If a 
potential donor has visited one of these provinces, they will 
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not be considered eligible for donation, unless laboratory test 
results for WNV are negative; 
• For organ donors, a case by case evaluation is conducted in 
order to assess the infection risk, which is acknowledged to 
be very low, taking into account the nature and benefits of 
transplantation and the health status of the patient on the 
waiting list.
Discussion
In the case of organ donation, decisions have to take into account 
the shortage of organs available for transplant and the great, usually 
life-saving, benefit that can result from this type of transplantation. 
The available time is very limited and it may not always be possible 
for WNV testing to be performed in a particular area of Italy where a 
donor is identified in time before the transplantation would need to 
proceed. Under such circumstances, the risk posed by a potential 
donor who may have spent a night in a WNV-affected area in the 
previous month and has had no symptoms of infection would be 
very low and would probably not justify depriving the recipients of 
the opportunity for transplantation. For this reason, it is necessary 
to consider each case individually, weighing the risks and potential 
benefits that face each individual recipient in a balanced and 
pragmatic way. 
In the case of tissue donation, the potential donor pool is much 
larger and shortages are therefore not a major challenge in the 
system, particularly in Italy where tissue donation rates are high. 
In general, tissue transplants result in improved quality of life 
and are rarely life-saving, so it is important to maintain risk at 
a very low level. On the other hand, many donated tissues are 
processed by washing, freezing, freeze-drying and in some cases 
subjected to gamma irradiation or other types of sterilisation. The 
tissues that are not highly processed, such as corneas, heart valves 
and skin, contain very little blood. The risk of an infected tissue 
transmitting a virus is therefore significantly lower than for blood or 
organs. Overall, it is considered appropriate to take a precautionary 
approach to the selection of tissue donors until there is a clearer 
picture of the extent of the problem.
The guidance described here will be reviewed should further 
infections be reported, also taking into account changing 
seasons.
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